CD163 and neoplasm: Moreover, we developed a three-tiered integrated risk stratification model incorporating mitotic count, density of Ki-67+ and CD163+ cells, and MTOR mutation to more accurately identify SFT patients of primary non-CNS and CNS SFTs with negative tumor margins (NTM) at high risk for tumor progression (Fig. 1).